Speciality: Critical Care
Description:
Welcome to our podcast on critical care. Today, we’re exploring how clinical guidelines shape everyday decisions in the intensive care unit. Guidelines are developed by experts and based on the latest evidence. They aim to standardise care, reduce errors, and improve patient outcomes. But turning guidelines into practice isn’t always straightforward. Each patient is unique, and clinicians must balance protocols with individual needs. Collaboration among the care team is key, as is staying up to date with new research. Ultimately, the goal is to combine evidence-based recommendations with clinical judgement, ensuring every patient receives the best possible care. Thanks for joining us as we bridge the gap from guidelines to practice in critical care.
See More Webinars @ Hidoc Webinars
1.
New surgical method shows promising results for cervical cancer treatment
2.
Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth
3.
GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium
4.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
5.
Can Prior Authorization Be Better With Artificial Intelligence?
1.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
2.
Public Health Strategies for Improving Cancer Survivorship Support Systems
3.
Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations
4.
Treating Methemoglobinemia: What You Need to Know Now!
5.
Red Cell Deformability as a Target in Critical Illness
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
2.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
5.
Updates on Standard V/S High Risk Myeloma Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation